Sonja Roach
Family · Moose Lake, MNNPI 1396770772
Payments from drug & device makers
Across 42 payments — averaging $14.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$83
- Astellas Pharma US Inc$74
- Amgen$42
- E.r. Squibb & Sons, L.L.C.$30
- Baxter Healthcare$30
- Novartis$29
- plus $340 from 20 others
What the payments were for
- Food & beverage$627100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 6 | $83 |
| Astellas Pharma US Inc | 4 | $74 |
| Amgen(2 entities) | 3 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Baxter Healthcare | 2 | $30 |
| Novartis | 2 | $29 |
| Medtronic | 2 | $29 |
| AbbVie | 2 | $27 |
| Pfizer | 2 | $26 |
| Tempus AI, Inc | 1 | $24 |
| Novavax Inc | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Bayer | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Roche Diagnostics Corporation | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Cepheid | 1 | $15 |
| Ardelyx, Inc. | 1 | $14 |
| Gilead | 1 | $13 |
| Myovant Sciences Inc. | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
| Organon | 1 | $9 |
| Phathom Pharmaceuticals, Inc. | 1 | $7 |
How this compares
$627 in reported general payments places this provider in the 85th percentile of 1,121 family providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $140,029 |
| EliquisApixaban | 76 | $57,007 |
| XareltoRivaroxaban | 56 | $51,975 |
| JardianceEmpagliflozin | 33 | $28,892 |
| RybelsusSemaglutide | 21 | $22,644 |
| MounjaroTirzepatide | 18 | $18,611 |
| JanuviaSitagliptin Phosphate | 25 | $17,789 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $17,416 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $14,875 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $14,705 |
| MyrbetriqMirabegron | 26 | $13,286 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $12,762 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $11,998 |
| Xigduo XrDapaglifloz Propaned/Metformin | 16 | $8,959 |
| DapagliflozinDapagliflozin Propanediol | 13 | $8,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $26 | $57,00776 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $17 | $34,19044 claims |
| Astellas Pharma US IncMyrbetriq | $74 | $13,28626 claims |
| AstraZenecaSymbicort | $83 | $3,39513 claims |
| AbbVieSynthroid | $27 | $1,44020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,121 family providers in Minnesota.
Other family in Moose Lake
- Erin HewittMinnetonka$172K
- Julia GourdeMinneapolis$65K
- Robin DontaMinneapolis$60K
- Kristin WeberMinneapolis$35K
- Crista WenischBurnsville$30K
- Kathleen FredellMinneapolis$28K
- Christina RichardsonNorthfield$27K
- Diana CzelMinneapolis$24K
- Alesya ShumkovMinnetonka$22K
- Michelle HigginsStewartville$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.